What is Prolocor?
Prolocor is a specialized medical technology firm dedicated to the development of advanced diagnostic tools for cardiovascular disease management. The company addresses a significant gap in current clinical practice by offering a precise method to assess individual patient risk through the quantification of FcyRIIa, a protein found on the surface of platelets. This innovative approach moves beyond traditional risk assessment models, empowering physicians to make more informed, individualized treatment decisions. By integrating its diagnostic solutions into the standard of care, Prolocor aims to enhance the efficacy of cardiovascular therapies and improve long-term patient health metrics. The company operates at the intersection of biotechnology and clinical diagnostics, leveraging deep scientific research to solve persistent challenges in heart health.
How much funding has Prolocor raised?
Prolocor has raised a total of $4.9M across 2 funding rounds:
Angel/Seed
$3.2M
Debt
$1.7M
Angel/Seed (2022): $3.2M with participation from Labcorp and Green Park & Golf Ventures
Debt (2024): $1.7M led by Green Park & Golf Ventures and Labcorp
Key Investors in Prolocor
Labcorp
Labcorp is a global leader in laboratory services, providing comprehensive diagnostic information to healthcare providers, pharmaceutical companies, and patients to facilitate confident medical decision-making.
Green Park & Golf Ventures
Green Park & Golf Ventures is a Dallas-based venture capital firm that leverages decades of operational experience to provide strategic backing and financial support to innovative medical start-ups.
What's next for Prolocor?
With the successful closure of this major enterprise-level funding, Prolocor is well-positioned to transition into its next phase of clinical validation and commercial scaling. The strategic capital will likely be deployed to refine its diagnostic platform, support ongoing clinical trials, and strengthen its regulatory pathway. As the company continues to demonstrate the clinical utility of its platelet-based testing, it is expected to forge deeper partnerships with healthcare providers and diagnostic laboratories. The focus remains on establishing a new standard for precision diagnostics, ultimately aiming to reduce the incidence of adverse cardiovascular events through early, accurate, and personalized risk stratification.
See full Prolocor company page
